Market Overview

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Ampio Pharmaceuticals, Inc. – AMPE


Rosen Law Firm, a global investor rights law firm, announces it is
investigating potential securities claims on behalf of shareholders of
Ampio Pharmaceuticals, Inc. (NYSE:AMPE) resulting from allegations that
Ampio may have issued materially misleading business information to the
investing public.

On August 7, 2018, during aftermarket hours, Ampio filed a Form 8-K with
the SEC providing a regulatory update on the FDA's review of Ampion,
including the AP-003-A and AP-003-C trials. Ampio disclosed that it met
with the FDA in July 2018 and received a response letter thereto, which
stated that "as a single trial[,] the AP-003-A study alone does not
appear to provide sufficient evidence of effectiveness to support [the
Biologics License Application]." The FDA further provided that "the FDA
does not consider the AP-003-C trial to be an adequate and
well-controlled clinical trial." On this news, shares of Ampio's stock
fell sharply during intraday trading on August 8, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Ampio investors. If you purchased shares of Ampio please
visit the firm's website at
to join the class action. You may also contact Phillip Kim or Zachary
Halper of Rosen Law Firm toll free at 866-767-3653 or via email at

Follow us for updates on LinkedIn:
or on Twitter:

Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class
Action Services for number of securities class action settlements in
2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View Comments and Join the Discussion!